CN114129584A - Application of phillyrin, phillyrin derivatives and composition of phillyrin and forsythiaside in resisting cytomegalovirus - Google Patents

Application of phillyrin, phillyrin derivatives and composition of phillyrin and forsythiaside in resisting cytomegalovirus Download PDF

Info

Publication number
CN114129584A
CN114129584A CN202010923837.9A CN202010923837A CN114129584A CN 114129584 A CN114129584 A CN 114129584A CN 202010923837 A CN202010923837 A CN 202010923837A CN 114129584 A CN114129584 A CN 114129584A
Authority
CN
China
Prior art keywords
phillyrin
forsythin
forsythiaside
glucuronide
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010923837.9A
Other languages
Chinese (zh)
Inventor
鲁明明
王硕
惠敏
刘国友
富力
柳洋
鲁岐
冯雪
周庆丰
付文斐
衣小凤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202010923837.9A priority Critical patent/CN114129584A/en
Priority to CN202180050269.9A priority patent/CN115955975A/en
Priority to KR1020237011165A priority patent/KR20230061471A/en
Priority to JP2023514428A priority patent/JP2023539681A/en
Priority to PCT/CN2021/115584 priority patent/WO2022048529A1/en
Priority to EP21863593.6A priority patent/EP4209225A1/en
Priority to BR112023003935A priority patent/BR112023003935A2/en
Priority to US18/024,173 priority patent/US20230338454A1/en
Priority to CA3190270A priority patent/CA3190270A1/en
Publication of CN114129584A publication Critical patent/CN114129584A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/288—Taraxacum (dandelion)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/35—Caprifoliaceae (Honeysuckle family)
    • A61K36/355—Lonicera (honeysuckle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/489—Sophora, e.g. necklacepod or mamani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539—Scutellaria (skullcap)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention discloses a new application of phillyrin, phillyrin derivatives, and phillyrin-phillygenin composition in preparation of health products and medicines for preventing and treating human cytomegalovirus infection related diseases. The related diseases comprise simple human cytomegalovirus infection of patients and the infection of the patients with human cytomegalovirus in the prevention and treatment process of cardiovascular and cerebrovascular diseases, organ transplantation, perinatal period, tumor, burn, AIDS and other diseases. Experiments prove that the phillyrin, the phillyrin derivatives, the phillyrin and phillygenin composition has obvious curative effect, quick response and small toxic and side effects in preventing and treating human cytomegalovirus infection diseases, is a safe, efficient and stable health-care product or medicament for treating human cytomegalovirus infection with simple preparation process, is suitable for industrial production and is easy to popularize. The invention provides a new health product source and a new medicine source for preventing and treating human cytomegalovirus infection.

Description

Application of phillyrin, phillyrin derivatives and composition of phillyrin and forsythiaside in resisting cytomegalovirus
Technical Field
The invention belongs to the field of health-care food and medicine, relates to a health-care product or medicine for preventing and treating human cytomegalovirus infection, and particularly relates to application of phillyrin, phillyrin derivatives or a phillyrin and phillygenin composition in the health-care product or medicine for preventing and treating human cytomegalovirus infection.
Background
Human Cytomegalovirus (HCMV), also known as cytoinclusion virus, is named because of the swelling of infected cells and the large nuclear inclusion bodies. HCMV belongs to the sub-family of beta herpesviridae, is about 200nm in diameter, is one of the largest animal viruses, has a 64nm inner core containing viral DNA, and is surrounded by a 110nm 20-sided body. The intact particle is enveloped by a capsule, which consists of at least 25-30 proteins or glycoproteins encoded by the viral particles constituting a BJ. The genome length of HCMV is about 235-240 kb, and the molecular weight is 150-160 multiplied by 103kDa, linear double-stranded DNA, belonging to the DNA virus. HCMV consists of two components or segments, long (L) and short(s). The structure of the DNA molecule has 4 kinds of isomers because the two components are in different directions or inverted at the mutual connection position. It is widely distributed, and other animals can suffer from infection, causing infections of all systems, mainly diseases of genitourinary system, central nervous system and liver, from mild asymptomatic infection to serious defect or death.
The HCMV gene structurally contains segments encoding 3 polypeptides specific for infected cells: immediate early protein region, late protein, 3 proteins are immunogenic and time-phased. The transcription and translation of HCMV are regulated and controlled by the HCMV transcription and translation vector and the expression of an immediate early gene and an early gene are regulated and controlled by a promoter, the detection is frequently seen in acute infection, the transcription and translation of a late gene are regulated and controlled by IE, E genes and proteins, the detection marks that the virus is in a latent stage, the virus is assembled and matured, and the late result of HCMV infection is obtained. There are 3 morphological transformation regions on the HCMV genome, namely mtrI, mtrII and mtrIII, which induce cell transformation. mtrI is located on the E fragment of Hind III at the left end of ADl69 strain genome U, is 588bp in length, and can transform NIH3T3 and primary mouse embryo cells. mtrII is located on Xbal/Bam HI EM fragment of HCMV Towne strain DNA, has the length of 980bp, can transform NIH3T3 and rat-2 cells, has corresponding regions on ADl69 and TdCMV Tanaka strains of HCMV, and contains 2 separated promoters P1 and P2, and mtrII exists in all transformed cells and tumor cells formed by the transformed cells. mtrIII is located on the Xbal/BamHI fragment and encodes a major immediate early protein with a molecular weight of 72kD, which is involved in viral inactivation and autoregulation, mtrIII is not present in transformed cells.
At the cellular level, infections are divided into 3 types: firstly, toxic infection is generated; ② latent infection; ③ transformation or latent carcinogenesis of cells. In vitro test HCMV can form a cell strain containing virus antigen after being inoculated to human fibroblasts and has the characteristic of transforming cells. Specific fragments of HCMV-DNA are extracted to transfect cells, and some cells are transformed by DNA integration into cell chromosomal DNA, and inoculated to athymic nude mice to generate tumors. Liu dynasty et al applied HCMV IE transfection to establish an HPV immortalized human cervical epithelial cell line, and found that HCMV is integrated into cell chromosomes, and cooperates with HPV16 to promote malignant transformation of the cervical epithelial cells and form tumors in nude mice, thereby indicating that the HCMV is closely related to cervical cancer. Ludwigia et al were inoculated to the cervix of the uterus of mice using uv-inactivated HCMV 3 times per week for 8 weeks. As a result, the cervical precancerous lesion rate of the HCMV group was 27.8% (23/83), and the carcinogenesis rate was 20.5% (17/83).
CMV has a typical herpes virus morphology, also similar in DNA structure to HSV, but 5% greater than HSV. The virus has high species specificity to host or cultured cells, and Human Cytomegalovirus (HCMV) only infects human and proliferates in human fiber cells. The virus is slowly proliferated in cell culture, the replication cycle is long, the cytopathic effect occurs only after 30-40 days of primary separation culture, and the virus is characterized in that the cells are enlarged and become a garden, the nucleus is enlarged, and a large eosinophilic inclusion body with a circle of 'halo' around the nucleus occurs in the nucleus. The cellular immune function of the body plays an important role in the occurrence and development of CMV infection, and a cell immunodeficiency person can cause serious and long-term CMV infection and further inhibit the cellular immunity of the body, such as the reduction of the activity of killer T cells, the reduction of the NK cell function and the like. The organism can produce specific antibody and killer T lymphocyte after primary CMV infection, and activate NM cell. Antibodies have limited CMV replication ability, are somewhat resistant to reinfection with the same strain, but are not resistant to activation by endogenous latent viruses, and are exogenously infectious with other different strains of CMV. While the greatest antiviral effect is achieved by specific killer T lymphocytes and antibody-dependent cytotoxic cells.
HCMV is extremely common in humans and can cause a variety of diseases. Adult infections are often seen in an immunodeficient or immunosuppressive state. Particularly, most patients are treated by immunosuppressive agents after organ transplantation and bone marrow transplantation, and patients with malignant tumors are treated by radiotherapy and chemotherapy. Is highly susceptible to HCMV infection. Patients with AIDS also have high HCMV hair dyeing degree. Because of the universality of HCMV infection and the serious consequences, the HCMV infection is highly valued worldwide, and has very important significance for epidemiology, diagnostic technology, treatment and prevention of HCMV infection and related virology basic research. The tumor patients receive chemotherapy or radiotherapy. The immune function is much lower than that of normal people, latent Human Cytomegalovirus (HCMV) is easy to reactivate to cause serious infection, and the latent human cytomegalovirus is an important infection factor influencing the survival rate and the life quality of tumor patients.
Cytomegalovirus infection is congenital or acquired infection caused by Cytomegalovirus (CMV), congenital or acquired infection caused by CMV, CMV is a double-stranded DNA virus, belongs to the group of herpesviruses, has a morphology similar to that of other herpesviruses, has obvious species specificity to host or tissue culture cells, and human CMV can only be isolated and cultured in human embryonic fibroblasts.
HCMV is infected widely in people, the adult infection rate of China reaches more than 95%, and adult infection is frequently caused in the immunodeficiency or immunosuppression state. Particularly, most patients are treated by immunosuppressive agents after organ transplantation and bone marrow transplantation, and patients with malignant tumors are treated by radiotherapy and chemotherapy. Is highly susceptible to HCMV infection. Most infected individuals are asymptomatic, but under certain conditions, affecting multiple organs and systems can produce severe disease. The virus can invade lung, liver, kidney, salivary gland, mammary gland and other glands, and multinuclear leucocyte and lymphocyte, and can be discharged from saliva, milk sweat blood, urine, semen, uterus secretion for a long time or intermittently. Usually, the drug is transmitted by multiple routes such as oral cavity, genital tract, placenta, blood transfusion or organ transplantation.
Congenital infection of pregnant women HCMV infection can cause congenital infection by placenta invading the fetus, with a few resulting in premature, abortive, stillbirth or postnatal death. Infants can develop jaundice, hepatosplenomegaly, thrombocytopenic purpura and hemolytic anemia. The surviving children often remain with permanent mental retardation, neuromuscular dyskinesia, deafness, choroid retinitis and the like.
(II) when the perinatal period infects the urinary tract and cervix of a parturient to discharge HCMV, the baby can be infected through the delivery tract during delivery, most of the infection is subclinical bed infection with mild symptoms or no clinical symptoms, and some of the infection has mild respiratory tract disorder or liver function damage.
Infection in children and adults is usually of a subclinical type, and may also lead to heterophilic antibody-negative mononucleosis, due to infection by breast pumping, kissing, sexual contact, blood transfusion, etc. The factors of pregnancy, immunosuppression treatment, organ transplantation, tumor, etc. activate the virus latent in monocyte and lymphocyte, resulting in mononucleosis, hepatitis, interstitial pneumonia, retinitis, encephalitis, etc.
(IV) cell transformation and possible carcinogenesis HCMV inactivated by UV light can transform rodent embryonic fibroblasts. The detection rate of HCMV DNA is high in some tumors such as cervical cancer, colon cancer, prostate cancer and Kaposis sarcoma, the HCMV antibody titer is also higher than that of normal people, and virus particles are also found in cell strains established by the tumors, which indicates that the HCMV has the potential carcinogenic possibility like herpes virus. The tumor patients receive chemotherapy or radiotherapy. The immune function is much lower than that of normal people, latent Human Cytomegalovirus (HCMV) is easy to reactivate to cause serious infection, and the latent human cytomegalovirus is an important infection factor influencing the survival rate and the life quality of tumor patients.
Most of the patients infected with HCMV are in a latent infection state; even though HCMV replicates in vivo, it is often asymptomatic. At present, no effective and safe anti-HCMV medicament exists, so the treatment of HCMV infection is still limited to symptomatic treatment during symptomatic infection; ganciclovir is only used with caution in symptomatic infection due to its toxic side effects such as bone marrow suppression. Ganciclovir (ganciclovir rDHG) has the function of preventing HCMV diffusion. If the combination is used with high-titer anti-HCMV immunoglobulin, the death rate of HCMV pneumonia complication of bone marrow transplantation can be reduced, and if the HCMV infection resistant to the propoxyguanosine is selected from sodium foscarnet, the HCMV diffusion can be reduced durably, but the effect is poorer than that of the former. The HCMV virus live vaccine developed abroad can induce the generation of antibodies, but the carcinogenic potential of the vaccine is excluded and needs to be solved.
The forsythia is one of the traditional Chinese medicines commonly used in clinic, has wide application and large dosage, has the functions of clearing heat, detoxifying, reducing swelling, dissipating binds and removing free radicals, is usually prepared into a formula with other Chinese herbal medicines in clinic and is used for treating various virus infection diseases. The inventor prepares and extracts the active monomer compounds of the forsythin and the forsythiaside through hard exploration, prepares the forsythin derivatives through chemical synthesis, and conducts a series of pharmacological activity researches to find that the composition of the forsythin, the forsythin derivatives, the forsythin and the forsythiaside has the function of treating human cytomegalovirus infection, and opens up a new prevention and treatment way for the diseases.
Figure BDA0002667647370000041
The inventor extracts the active ingredients of the forsythin, the composition of the forsythin and the forsythiaside from forsythia and forsythia leaves by a large amount of modern scientific research and by adopting an advanced separation and purification technology, and prepares the forsythin derivative by further research and synthesis, and can provide a high-efficiency and low-toxicity health care product and medicine for susceptible people and patients of human cytomegalovirus.
Disclosure of Invention
The invention aims at the technical problems of treating human cytomegalovirus infection diseases, and provides new application of phillyrin, phillyrin derivatives and phillyrin-phillygenin compositions (phillyrin/phillygenin) in preparing health care products and medicines for preventing and treating cytomegalovirus (especially human cytomegalovirus) infection diseases.
On one hand, the invention provides the application of phillyrin, phillyrin derivatives or a phillyrin and phillygenin composition in the preparation of health products or medicines for resisting cytomegalovirus; correspondingly, the application of the phillyrin, the phillyrin derivative or the phillyrin and phillygenin composition in preparing health care products or medicines for preventing and treating diseases caused by cytomegalovirus infection is also provided. The health product or the medicine contains phillyrin, phillyrin derivatives or a composition of phillyrin and phillygenin as active ingredients, and is used for resisting cytomegalovirus or preventing and treating human cytomegalovirus infection diseases or diseases.
Wherein the cytomegalovirus is human cytomegalovirus, and accordingly the disorder is a disorder caused by human cytomegalovirus infection. The disease comprises the simple human cytomegalovirus infection disease of a patient, the infection of the patient by the human cytomegalovirus in the treatment process of cardiovascular and cerebrovascular diseases, tumors, burns or AIDS, and the infection of the patient by the human cytomegalovirus in organ transplantation or perinatal period.
The forsythin/forsythiaside composition consists of forsythin and forsythiaside monomers, or is a forsythiaside-forsythiaside extraction composition prepared by adopting a solvent heating extraction method, or is a forsythiaside-cyclodextrin composition formed by combining forsythiaside, forsythiaside and cyclodextrin or cyclodextrin derivatives.
In particular, the forsythiaside-phillyrin-cyclodextrin composition is a mixture formed by mixing forsythiaside and phillyrin with alpha-, beta-or gamma-cyclodextrin or derivatives thereof, or a compound formed by physically and chemically treating the forsythiaside and phillyrin with alpha-, beta-or gamma-cyclodextrin or derivatives thereof.
In particular, the weight ratio of forsythin and forsythin to cyclodextrin or cyclodextrin derivative in the forsythin-cyclodextrin composition is 1: 1-50.
In particular, the cyclodextrin is alpha-or beta-, gamma-cyclodextrin; the cyclodextrin derivative is hydroxyethyl-cyclodextrin, 2, 6-dimethyl-cyclodextrin, 2,3, 6-trimethyl-cyclodextrin, 2, 6-diethyl-cyclodextrin, 2,3, 6-triethyl-cyclodextrin, maltosyl-cyclodextrin or sulfobutylether beta-cyclodextrin, p-toluenesulfonyl chloride (p-TsCl) -substituted beta-cyclodextrin, 6-substituted beta-CD p-toluenesulfonate (. beta. -cyclodextrin-6-OTs), 2-oxopropyl-. beta. -cyclodextrin, 2-monosubstituted p-toluenesulfonate (. beta. -cyclodextrin-2-OTs), β -cyclodextrin p-toluenesulfonate (Tosyl-. beta. -CD), star macromolecule PCL- (Tos) 7-. beta. -CD of β -cyclodextrin.
In particular, the weight ratio of the forsythin to the forsythiaside composition is 2-99.99: 0.01-98, preferably 80-99: 1-20, more preferably 90-98:2-10, such as 98:2 or 90: 10.
Wherein the phillyrin derivative is preferably a phillygenin glucuronic acid derivative. In particular, the forsythin derivatives include, but are not limited to, 33-Hydroxy-forsythiaside (33-Hydroxy-phenicolin-8-O-. beta. -D-glucuronide), 9-Hydroxy-forsythiaside (9-Hydroxy-phenicolin-8-O-. beta. -D-glucuronide), 33, 34-methylenedioxy-forsythiaside (33, 34-methylenedioxy-forsythiaside-8-O-. beta. -D-glucuronide), forsythiaside methyl ester ((2R,3R,4R,5S) -methyl6- (5- ((1R,4S) -4- (3,4-dimethoxyphenyl) hexahydrofuro [3,4-c ] furan-1-yl) -2-methoxy) -3,4, 5-tetrahydroxy-2H-pyran-2-carboxylate), sodium forsythiaside (sodium (2R,3R,4R,5S) -6- (5- ((1R,4S) -4- (3,4-dimethoxyphenyl) hexahydrofuro [3,4-c ] furan-1-yl) -2-methoxyphenoxy) -3,4, 5-tetrahydroxy-2H-pyran-2-carboxylate), potassium forsythiaside (2R,3R,4R,5S) -6- (5- ((1R,4S) -4- (3,4-dimethoxyphenyl) hexahydrofuro [3,4-c ] furan-1-yl) -2-phenoxyoxy) -2, 5-tetrahydroxy-2H-carboxylate), potassium forsythiaside (2R,3R, 4-C ] furan-1-yl) hexahydrofuro [3,4-c ] hexahydro-1-hexahydrofuro) -2-phenoxyoxy) -2, 4-phenoxyoxy-2H-carboxylate), 2-carboxyxanthate, Forsythiaside glucuronic acid ((2R,3R,4R,5S) -6- (5- ((1R,4S) -4- (3,4-dimethoxyphenyl) hexahydrofuro [3,4-c ] furan-1-yl) -2-methoxyphenoxy) -3,4, 5-tetrahydroxytran-2H-pyran-2-carbooxyacid); preferably 33-hydroxy-forsythiaside, 9-hydroxy-forsythiaside, 33, 34-methylenedioxy-forsythiaside glucuronide, methyl forsythiaside, sodium forsythiaside or potassium forsythiaside.
Wherein the content of the phillyrin, the phillyrin derivatives, and the phillyrin-phillygenin composition is more than or equal to 1%, preferably more than or equal to 30%, more preferably more than or equal to 60%, more preferably more than or equal to 80%, and more preferably more than or equal to 98%.
Wherein the weight ratio of the phillyrin, the phillyrin derivative or the phillyrin-phillygenin composition to the total weight of the health-care product or the medicine is 0.01-50: 100.
the medicine comprises phillyrin, phillyrin derivatives or a phillyrin-phillygenin composition and a pharmaceutically acceptable carrier, and preferably consists of phillyrin, phillyrin derivatives or a phillyrin-phillygenin composition and a pharmaceutically acceptable carrier.
The health-care product comprises phillyrin, phillyrin derivatives or a phillyrin-phillygenin composition and a carrier or food additive acceptable in the health-care product or food, and preferably consists of phillyrin, phillyrin derivatives or a phillyrin-phillygenin composition and a carrier or food additive acceptable in the health-care product or food.
In particular, pharmaceutically acceptable carriers are generally approved by health care professionals for this purpose and as inactive ingredients of medicaments. A compilation of pharmaceutically acceptable carriers can be found in tools such as The Handbook of Pharmaceutical excipients (Handbook of Pharmaceutical excipients, 2 nd edition, edited by A.Wade and P.J.Weller; published by American Pharmaceutical Association, Washington and The Pharmaceutical Press, London, 1994).
In particular, food additives are non-nutritive substances that are intentionally added to food, generally in small amounts, to improve the appearance, flavor, texture, or storage properties of the food. The related food additives can be found in the national food safety standard 'food additive use standard'.
In particular, the carrier includes excipients such as starch, water, and the like; lubricants, such as magnesium stearate and the like; disintegrants, such as microcrystalline cellulose and the like; fillers, such as lactose and the like; binders such as pregelatinized starch, dextrin, and the like; a sweetener; an antioxidant; preservatives, flavoring agents, perfumes, and the like;
in particular, the medicament is in the form of tablets, capsules, pills, powders, granules, syrups.
In particular, the health care product exists in the forms of tablets, capsules, pills, powder, granules and syrup, and also exists in the forms of dairy products, candies, beverages, biscuits, tea leaves and related products, wines and other food products.
In particular, the medicine or health product also comprises evodia rutaecarpa extract, ginger extract, amomum villosum extract, amomum cardamomum extract, alpinia katsumadai extract, caulis bambusae in taeniam extract, reed rhizome extract, pinellia ternate extract, clove extract, inula flower extract, loquat leaf extract, calyx kaki extract, sword bean extract, ruddle extract, agastache rugosus extract, agilawood extract, perilla extract, vitamin C and derivatives thereof or vitamin E and derivatives thereof.
Compared with the prior art, the invention has the following obvious advantages:
1. a series of experimental researches prove that the phillyrin, the phillyrin derivatives, and the phillyrin-phillygenin composition have the obvious effects of preventing, relieving and treating cytomegalovirus infection diseases of human.
2. The phillyrin, phillyrin derivatives, phillyrin and phillygenin composition has strong pharmacological action, obvious effects of preventing, relieving, conditioning, inhibiting and treating human cytomegalovirus infection diseases, quick response, small toxic and side effects, good safety, long-term taking and good application prospect.
3. The product of the invention has rich raw material sources, low price, safe clinical use, simple preparation process, small dosage and convenient use, can be prepared into various dosage forms, and is easy to popularize.
4. The invention can adopt single component phillyrin, phillyrin derivative active component, phillyrin and phillygenin composition to prepare the medicine for preventing, relieving and treating human cytomegalovirus infection diseases, and can also be prepared into compound medicines for preventing and treating human cytomegalovirus infection diseases by adopting a common formula of phillyrin, phillyrin derivatives, phillyrin and phillygenin compositions and other active ingredients (such as evodia rutaecarpa extract, ginger extract, amomum villosum extract, amomum cardamomum extract, katsumadai seed extract, galangal rhizome extract, bamboo shavings extract, reed rhizome extract, pinellia tuber extract, clove extract, inula flower extract, loquat leaf extract, kaki calyx extract, sword bean extract, ruddle extract, agastache rugosus extract, agilawood extract, perilla extract, vitamin C and derivatives thereof or vitamin E and derivatives thereof).
5. The product of the invention has safe raw materials, can be eaten in daily life or taken for a long time, can be prepared into food forms such as dairy products, candies, beverages, biscuits, tea leaves and related products, wine and the like, is selected by the broad masses, and increases the applicability.
6. The invention develops new medicinal values for known compounds of phillyrin and phillygenin, the phillyrin and the phillygenin can be used for preventing, relieving and treating human cytomegalovirus infection diseases, and can be prepared into health-care food or medicine for preventing, relieving or/and treating the human cytomegalovirus infection diseases, thereby developing a new field for the application of the medicinal materials of forsythia suspensa and forsythia suspensa leaves.
Detailed Description
The beneficial effects of the formulation of the present invention are further described by the following specific embodiments, which include the preparation test and pharmacodynamic test of the phillyrin, phillyrin derivatives, and phillyrin-phillygenin composition of the present invention in capsule, granule, tablet, granule, and soft capsule. These examples are merely illustrative and do not limit the scope of the present invention in any way. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.
The forsythin derivatives 33-hydroxy-forsythiaside glucuronide, 9-hydroxy-forsythiaside glucuronide and 33, 34-methylenedioxy-forsythiaside of the present invention are the same as the forsythin derivatives described in the patent application (application No. 201510319303.4, priority No. 201510164294.6); forsythiacetol methyl glucuronate, forsythol sodium glucuronate, forsythol potassium glucuronate, forsythol glucuronic acid are the same as in the patent application (application No.: 201510320579.4, priority No.: 201410825547.5).
EXAMPLE 1 Forsythiaside tablet
1. The raw materials are prepared according to the following mixture ratio
Figure BDA0002667647370000081
2. Mixing phillyrin and starch uniformly, granulating, adding pulvis Talci and magnesium stearate, mixing uniformly, and pressing into 10000 tablets.
Example 2 Forsythiaside capsules
1. The raw materials are prepared according to the following mixture ratio
Forsythiaside (purity 60%) 200g
Starch 1000g
2. Mixing phillyrin and starch uniformly, and encapsulating to obtain 10000 granules.
Example 3 Forsythiaside Capsule
1. The raw materials are prepared according to the following mixture ratio
Forsythiaside (purity 98%) 500g
Starch 1000g
2. Mixing phillyrin and starch uniformly, and encapsulating to obtain 10000 granules.
EXAMPLE 4 Forsythiaside tablet
1. The raw materials are prepared according to the following mixture ratio
Figure BDA0002667647370000091
2. Mixing phillyrin, fructus evodiae extract, vitamin C and starch uniformly, granulating, adding pulvis Talci and magnesium stearate, mixing uniformly, and pressing into 10000 tablets.
Example 5 Forsythiaside Capsule
1. The raw materials are prepared according to the following mixture ratio
Figure BDA0002667647370000092
2. Mixing phillyrin, rhizoma Alpiniae Officinarum extract, vitamin C and starch, and making into capsule with a size of 10000 granules.
Example 6 Forsythiaside granules
1. The raw materials are prepared according to the following mixture ratio
Figure BDA0002667647370000093
2. Mixing phillyrin, fructus Amomi extract, vitamin C and sucrose powder, granulating, and packaging into 10000 bags.
Example 7 Forsythiaside oral liquid
1. The raw materials are prepared according to the following mixture ratio
Figure BDA0002667647370000094
Figure BDA0002667647370000101
Dissolving phillyrin, caulis Bambusae in Taenia extract and rhizoma Phragmitis extract in ethanol, adding glucose syrup, adding deionized water to 100ml, and mixing.
Example 833-hydroxy-forsythin glucuronide tablet
1. The raw materials are prepared according to the following mixture ratio
Figure BDA0002667647370000102
2. Mixing 33-hydroxy-forsythiaside glucuronide and starch uniformly, granulating, adding pulvis Talci and magnesium stearate, mixing uniformly, and pressing into 10000 tablets.
Example 933-hydroxy-forsythiaside glucuronide capsules
1. The raw materials are prepared according to the following mixture ratio
33-hydroxy-forsythiaside glucuronide (purity 60%) 200g
Starch 1000g
2. Mixing 33-hydroxy-forsythiaside glucuronide and starch uniformly, and encapsulating to obtain 10000 capsules.
Example 1033-hydroxy-Forsythiaside glucuronide capsules
1. The raw materials are prepared according to the following mixture ratio
33-hydroxy-forsythiaside glucuronide (purity 98%) 500g
Starch 1000g
2. Mixing 33-hydroxy-forsythiaside glucuronide and starch uniformly, and encapsulating to obtain 10000 capsules.
Example 1133-hydroxy-forsythin glucuronide tablet
1. The raw materials are prepared according to the following mixture ratio
Figure BDA0002667647370000103
2. Mixing 33-hydroxy-forsythiaside glucuronide, fructus evodiae extract, vitamin C and starch uniformly, granulating, adding pulvis Talci and magnesium stearate, mixing uniformly, and pressing into 10000 tablets.
Example 1233-hydroxy-Forsythiaside glucuronide Capsule
1. The raw materials are prepared according to the following mixture ratio
Figure BDA0002667647370000111
2. Mixing 33-hydroxy-forsythiaside glucuronide, rhizoma Pinelliae extract, vitamin C and starch uniformly, and encapsulating to obtain 10000 capsules.
Example 1333-hydroxy-forsythin glucuronide granules
1. The raw materials are prepared according to the following mixture ratio
Figure BDA0002667647370000112
2. Mixing 33-hydroxy-forsythiaside glucuronide, fructus Amomi rotundus extract, vitamin C and sucrose powder, granulating, and packaging into 10000 bags.
Example 1433-hydroxy-Forsythiaside glucuronide oral liquid
1. The raw materials are prepared according to the following mixture ratio
Figure BDA0002667647370000113
2. Dissolving 33-hydroxy-forsythiaside glucuronide, fructus Amomi rotundus extract and fructus evodiae extract in ethanol, adding glucose syrup, and adding deionized water to 100 ml.
Example 159-hydroxy-Forsythiaside glucuronide tablet
1. The raw materials are prepared according to the following mixture ratio
Figure BDA0002667647370000114
Figure BDA0002667647370000121
2. Mixing 9-hydroxy-forsythiaside glucuronide and starch uniformly, granulating, adding pulvis Talci and magnesium stearate, mixing uniformly, and pressing into 10000 tablets.
Example 169-hydroxy-forsythin glucuronide capsules
1. The raw materials are prepared according to the following mixture ratio
200g of 9-hydroxy-forsythiaside glucuronide (purity 97%) (purity)
Starch 1000g
2. Mixing 9-hydroxy-forsythiaside glucuronide and starch uniformly, and encapsulating to obtain 10000 capsules.
EXAMPLE 179-hydroxy-Forsythiaside glucuronide Capsule
1. The raw materials are prepared according to the following mixture ratio
500g of 9-hydroxy-forsythiaside glucuronide (purity 98%)
Starch 1000g
2. Mixing 9-hydroxy-forsythiaside glucuronide and starch uniformly, and encapsulating to obtain 10000 capsules.
EXAMPLE 189-hydroxy-forsythin glucuronide tablet
1. The raw materials are prepared according to the following mixture ratio
Figure BDA0002667647370000122
2. Mixing 9-hydroxy-forsythiaside glucuronide, fructus evodiae extract, vitamin C and starch uniformly, granulating, adding pulvis Talci and magnesium stearate, mixing uniformly, and pressing into 10000 tablets.
Example 199-hydroxy-Forsythiaside glucuronide capsules
1. The raw materials are prepared according to the following mixture ratio
Figure BDA0002667647370000123
Figure BDA0002667647370000131
2. Mixing 9-hydroxy-forsythiaside glucuronide, rhizoma Pinelliae extract, vitamin C and starch uniformly, and encapsulating to obtain 10000 capsules.
Example 209-hydroxy-Forsythiaside glucuronide granules
1. The raw materials are prepared according to the following mixture ratio
Figure BDA0002667647370000132
2. Mixing 9-hydroxy-forsythiaside glucuronide, fructus Amomi rotundus extract, vitamin C and sucrose powder, granulating, and packaging into 10000 bags.
Example 219-hydroxy-Forsythiaside glucuronide oral liquid
1. The raw materials are prepared according to the following mixture ratio
Figure BDA0002667647370000133
2. Dissolving 9-hydroxy-forsythiaside glucuronide, fructus Amomi rotundus extract, and Inulae flos extract with ethanol, adding glucose syrup, and adding deionized water to 100 ml.
Example 2233, 34-methylenedioxy-Forsythiacet glucoside tablet
1. The raw materials are prepared according to the following mixture ratio
Figure BDA0002667647370000134
2. Mixing 33, 34-methylenedioxy-forsythiaside glucuronide and starch uniformly, granulating, adding pulvis Talci and magnesium stearate, mixing uniformly, and pressing into 10000 tablets.
Example 2333, 34-methylenedioxy-forsythiaside glucuronide capsules
1. The raw materials are prepared according to the following mixture ratio
33, 34-methylenedioxy-forsythiaside glucuronide (purity 97%) 200g
Starch 1000g
2. Mixing 33, 34-methylenedioxy-forsythiaside glucuronide and starch uniformly, and encapsulating to obtain 10000 capsules.
Example 2433, 34-methylenedioxy-Forsythiacetoglucoside Capsule
1. The raw materials are prepared according to the following mixture ratio
33, 34-methylenedioxy-forsythiaside glucuronide (purity 98%) 500g
Starch 1000g
2. Mixing 33, 34-methylenedioxy-forsythiaside glucuronide and starch uniformly, and encapsulating to obtain 10000 capsules.
Example 2533, 34-methylenedioxy-Forsythiacet glucoside tablet
1. The raw materials are prepared according to the following mixture ratio
Figure BDA0002667647370000141
2. Mixing 33, 34-methylenedioxy-forsythiaside glucuronide, inula flower extract, vitamin C and starch uniformly, granulating, adding talcum powder and magnesium stearate, mixing uniformly, and pressing into 10000 tablets.
Example 2633, 34-methylenedioxy-Forsythiacetoglucoside Capsule
1. The raw materials are prepared according to the following mixture ratio
Figure BDA0002667647370000142
2. Mixing 33, 34-methylenedioxy-forsythiaside glucuronide, pinellia ternate extract, vitamin C and starch uniformly, and encapsulating to obtain 10000 capsules.
Example 2733, 34-methylenedioxy-Forsythiaside glucuronide granules
1. The raw materials are prepared according to the following mixture ratio
Figure BDA0002667647370000151
2. Mixing 33, 34-methylenedioxy-forsythiaside glucuronide, fructus Amomi rotundus extract, vitamin C and sucrose powder, granulating, and packaging into 10000 bags.
Example 2833, 34-methylenedioxy-Forsythiacetoglucoside granules
1. The raw materials are prepared according to the following mixture ratio
Figure BDA0002667647370000152
2. Mixing 33, 34-methylenedioxy-forsythiaside glucuronide, fructus Amomi rotundus extract, vitamin C and sucrose powder, granulating, and packaging into 10000 bags.
Example 2933, 34-methylenedioxy-forsythiaside glucuronide oral liquid
1. The raw materials are prepared according to the following mixture ratio
Figure BDA0002667647370000153
2. Dissolving 33, 34-methylenedioxy-forsythiaside glucuronide, fructus Amomi rotundus extract and Inulae flos extract with ethanol, adding glucose syrup, and adding deionized water to 100 ml.
Example 30 Forsythiaside and Forsythiagenin composition tablet preparation
1. The tablets of the phillyrin/phillygenin composition are prepared according to the following mixture ratio:
Figure BDA0002667647370000154
2. taking 490g of phillyrin, 10g of phillygenin and starch, mixing well, granulating, adding talcum powder and magnesium stearate, mixing well, and pressing into 10000 tablets.
EXAMPLE 31 preparation of Forsythiaside/Forsythiagenin composition granules
1. The granules of the forsythin/forsythiaside composition are prepared according to the following mixture ratio:
phillyrin/phillygenin composition (98: 2) 100g
Microcrystalline cellulose 10000g
2. 98g of phillyrin, 2g of forsythiaside and microcrystalline cellulose are uniformly mixed, and then the mixture is prepared into granules which are packaged into 10000 bags.
EXAMPLE 32 Forsythiaside/Forsythiagenin composition Capsule preparation
1. A capsule of the phillyrin/phillygenin composition is prepared according to the following mixture ratio:
forsythiaside/forsythiaside composition (weight ratio of 98:2) 250g
2500g of starch
2. Taking 245g of phillyrin, 5g of forsythiaside and starch, uniformly mixing and encapsulating, and preparing 10000 granules.
EXAMPLE 33-36 Forsythiaside/Forsythiagenin composition Capsule preparation
In examples 33 to 36, the forsythin/forsythiaside compositions were mixed with starch in the weight ratios shown in the following table, and encapsulated into 10000 capsules.
Figure BDA0002667647370000161
Example 37-40 preparation of Forsythiaside/Forsythiaside composition granules
In examples 37 to 30, the forsythin/forsythiaside composition was mixed with microcrystalline cellulose at the weight ratios shown in the following table, and then granulated into granules and bagged into 10000 bags.
Figure BDA0002667647370000162
Figure BDA0002667647370000171
EXAMPLE 41 Forsythiaside/Forsythiagenin composition tablet preparation
1. The tablets of the phillyrin/phillygenin composition are prepared according to the following mixture ratio:
Figure BDA0002667647370000172
2. weighing 490g forsythin, 10g forsythiaside and herba Agastaches extract powder, mixing well, mixing with starch, granulating, adding pulvis Talci and magnesium stearate, mixing well, and pressing into 10000 tablets.
EXAMPLE 42 Forsythiaside/Forsythiagenin composition granule preparation
1. The granules of the forsythin/forsythiaside composition are prepared according to the following mixture ratio:
Figure BDA0002667647370000173
2. taking 245g of phillyrin, 5 parts of forsythiaside, agilawood extract and agastache extract powder, uniformly mixing with microcrystalline cellulose, preparing into granules, and bagging to obtain 10000 bags.
EXAMPLE 43 Forsythiaside/Forsythiagenin composition Capsule preparation
1. A capsule of the phillyrin/phillygenin composition is prepared according to the following mixture ratio:
Figure BDA0002667647370000174
2. 245g of phillyrin and 5g of phillygenin are uniformly mixed with the powder of the perilla extract, the loquat leaf extract and the clove extract, and then the mixture is uniformly mixed with starch and encapsulated to prepare 10000 capsules.
EXAMPLE 44 Forsythiaside/Forsythiagenin composition tablet preparation
1. The tablets of the phillyrin/phillygenin composition are prepared according to the following mixture ratio:
Figure BDA0002667647370000181
2. taking 490g of phillyrin, 10g of phillygenin and loquat leaf extract powder, mixing well with starch, granulating, adding talcum powder and magnesium stearate, mixing well, pressing, and making into 10000 tablets.
EXAMPLE 45 Forsythiaside/Forsythiagenin composition granule preparation
1. The granules of the forsythin/forsythiaside composition are prepared according to the following mixture ratio:
Figure BDA0002667647370000182
2. mixing phillyrin 900g and phillygenin 100g with the above extract (Inulae flos, rhizoma Pinelliae) powder, mixing with microcrystalline cellulose, granulating, and bagging to 10000 bags.
EXAMPLE 46 Forsythiaside/Forsythiagenin composition Capsule preparation
1. A capsule of the phillyrin/phillygenin composition is prepared according to the following mixture ratio:
Figure BDA0002667647370000183
2. 1880g forsythin and 120g forsythiaside are uniformly mixed with the extract (inula flower, katsumadai seed and loquat leaf) powder, and then the mixture is uniformly mixed with starch and encapsulated into 10000 capsules.
EXAMPLE 47 Forsythiaside/Forsythiagenin composition Soft Capsule preparation
1. The soft capsule of the phillyrin/phillygenin composition is prepared according to the following mixture ratio:
Figure BDA0002667647370000184
Figure BDA0002667647370000191
2. heating PEG-4002000 g, PEG-400026 g and propylene glycol 260g to 65 deg.C for melting, and stirring to obtain water soluble matrix; mixing with the composition, and stirring. Heating 5000 g of gelatin and 4500 g of water to 70 ℃, taking 1750 g of glycerol and 15 g of methyl hydroxybenzoate, stirring, vacuumizing for 1 hour, mixing with the gelatin, and standing overnight at 70 ℃. The preparation is carried out by an automatic soft capsule filling machine to obtain 10000 soft capsules.
Test example 1 Experimental study of phillyrin, phillyrin derivatives, and phillyrin-phillygenin composition against human cytomegalovirus in vitro
1 materials of the experiment
1.1 drugs and reagents:
phillyrin (batch No. 20130303), white powder, produced by DALIANFUSHENG Natural drug development Co. The purity is 99.5% by high performance liquid chromatography, and the content is 99.5% by using phillyrin reference substance for content determination of Chinese medicinal biological products.
33-hydroxy-forsythin glucuronide (phillyrin derivative A, batch No. 20130301), white powder, produced by DALIANGSHENG Natural drug development Co., Ltd. The purity of the product is 98.5% as determined by area normalization of two detectors (ultraviolet detector and evaporative light scattering detector) of high performance liquid chromatography.
9-hydroxy-forsythiaside glucuronide (phillyrin derivative B, batch number: 20130302), white powder, produced by DALIANGSHENG Natural drug development Co., Ltd. The purity of the product is 99.2% as determined by area normalization of two detectors (ultraviolet detector and evaporative light scattering detector) of high performance liquid chromatography.
33, 34-methylenedioxy-forsythiaside glucuronide (phillyrin derivative C, batch number: 20130301), white powder, produced by DALIANGHENGFEN Natural drug development Co., Ltd. The purity of the product is 98.7% as determined by area normalization of two detectors (ultraviolet detector and evaporative light scattering detector) of high performance liquid chromatography.
Phillyrin/phillygenin composition a (batch No. 20130305), white powder, manufactured by great lian fusheng natural drug development limited. Detecting the content by high performance liquid chromatography, wherein the content of phillyrin: forsythiaside is 98:2, the sum of the contents of phillyrin and phillygenin is 98.4%.
Phillyrin/phillygenin composition B (batch No. 20130306), white powder, produced by DALIANGSHENG Natural drug development Co. Detecting the content by high performance liquid chromatography, wherein the content of phillyrin: forsythiaside is 90:10, the sum of the contents of phillyrin and phillygenin is 98.1 percent.
Ganciclovir (GCV) powder for injection (trade name: Likewei, manufacturer: Hubeike Yi pharmaceutical products Co., Ltd., lot number: 091102)
1.2 viruses and cells
Human embryonic lung fibroblast cell line (purchased from Shanghai preferred Biotech, Inc.). The cells are cultured and subcultured according to a conventional method.
HCMV AD169 strain, purchased from American Type Culture Collection (ATCC).
2. Method of producing a composite material
2.1 viral virulence assay:
culturing cells and viruses according to a conventional method, carrying out passage and amplification, and determining HCMV AD169 strain TCD50Is 10-4.6。
2.2. Drug toxicity testing:
the maximum nontoxic concentration (TD) of each drug and GCV was measured by MTT and cytopathic method0) The results of both methods were consistent. The results are shown in Table 1.
2.3. Inhibition of HCMV
Cells were seeded in 96-well plates and after they grew into monolayers, 100-fold TCD was applied50Inoculating the cells with the virus challenge amount of (1). Subjecting each medicine to TD0At the beginning, diluting step by step according to a 10-time gradient to prepare 5 concentrations, and setting 4 holes for each concentration; 4 wells were also set for normal cell control and virus control. Cultured for 10 days, the minimum effective concentration MEC of the drug is examined, and the therapeutic index (TD) is calculated0/MEC). Specific data are shown in the following table.
TABLE 1 statistics of therapeutic index for drug versus control
Figure BDA0002667647370000201
Discussion of 3
In the experiment, antiviral drug ganciclovir is used as a contrast drug, and the inhibitory action of phillyrin, phillyrin derivatives, phillyrin and phillygenin composition on human cytomegalovirus in vitro is examined by applying a cell pathology method and an MTT method. The results show that the phillyrin, the phillyrin derivatives, the phillyrin and phillygenin composition have stronger in-vitro human cytomegalovirus inhibition effect, and have lower toxicity and higher therapeutic index than the control drug. The phillyrin, the phillyrin derivative, the phillyrin and phillygenin composition are suggested to have potential application prospects in clinical inhibition of cytomegalovirus.

Claims (10)

1. Application of phillyrin, phillyrin derivatives or phillyrin and phillygenin composition in preparation of anti-cytomegalovirus health products or medicines or health products or medicines for preventing or treating diseases caused by cytomegalovirus infection.
2. The use of claim 1, wherein the cytomegalovirus is human cytomegalovirus; and/or, the disease comprises the simple human cytomegalovirus infection disease of the patient, or the infection of the patient with the human cytomegalovirus in the treatment process of the cardiovascular and cerebrovascular diseases, tumors, burns or AIDS, or the infection of the patient with the human cytomegalovirus in organ transplantation or perinatal period.
3. The use according to claim 1, wherein the forsythin derivative is 33-Hydroxy-forsythin glucuronide (33-Hydroxy phenyl genin-8-O- β -D-glucuronide), 9-Hydroxy-forsythin glucuronide (9-Hydroxy phenyl genin-8-O- β -D-glucuronide), 33, 34-Methylenedioxy-forsythin glucuronide (33, 34-methoxy phenyl genin-8-O- β -D-glucuronide), methyl forsythin glucuronide ((2R,3R,4R,5S) -methyl6- (5- ((1R,4S) -4- (3,4-dimethoxyphenyl) hexahydrofuro [3,4-c ] furan-1-yl) -2-methoxy) -3,4, 5-tetrahydroxy tran-2H-pyran-2-carboxylate), sodium forsythiaside glucuronate (sodium (2R,3R,4R,5S) -6- (5- ((1R,4S) -4- (3,4-dimethoxyphenyl) hexahydrofuro [3,4-c ] furan-1-yl) -2-methoxyphenoxy) -3,4, 5-tetrahydroxytran-2H-pyran-2-carboxylate), potassium forsythiaside glucuronate (sodium (2R,3R,4R,5S) -6- (5- ((1R,4S) -4- (3,4-dimethoxyphenyl) hexahydrofuro [3,4-c ] furan-1-2-carboxylate) or ((2R, 4-dihydrotyrosyl) -2H-glucuronate), 3R,4R,5S) -6- (5- ((1R,4S) -4- (3,4-dimethoxyphenyl) hexahydrofuro [3,4-c ] furan-1-yl) -2-methoxyphenoxy) -3,4, 5-trihydroxymethyl-2H-pyran-2-carboxylic acid), preferably 33-hydroxy-forsythin glucuronide, 9-hydroxy-forsythin glucuronide, 33, 34-methylenedioxy-forsythin glucuronide, forsythin glucuronide methyl ester, forsythin glucuronide sodium or forsythin glucuronide potassium.
4. The use of claim 1, wherein the phillyrin-phillygenin composition consists of phillyrin and phillygenin, preferably wherein the weight ratio of phillyrin to phillygenin is 2-99.99: 0.01-98, preferably 80-99: 1-20.
5. The use according to claim 1, wherein the nutraceutical or pharmaceutical further comprises a nutraceutical, a food or a pharmaceutically acceptable excipient, such as a carrier or a food additive, preferably a cyclodextrin, such as α -, β -or γ -cyclodextrin or a derivative thereof.
6. The use of claim 5, wherein the health product or medicament is a mixture of forsythin, a forsythin derivative or a combination of forsythin and forsythiaside and α -, β -or γ -cyclodextrin or a derivative thereof, or a complex of forsythin, a forsythin derivative or a combination of forsythiaside and α -, β -or γ -cyclodextrin or a derivative thereof, which is physically and chemically treated.
7. The use of claim 1, wherein the medicament is in the form of a tablet, capsule, pill, powder, granule, syrup, solution, emulsion, injection, spray, aerosol, gel, cream, tincture, cataplasm, rubber patch or patch; or the health care product exists in the forms of tablets, capsules, pills, powder, granules, syrups, solutions and emulsions, or exists in the forms of dairy products, candies, beverages, biscuits, tea leaves and related products, wines and other food products.
8. The use of claim 1, wherein the content of forsythin, forsythin derivatives or a combination of forsythin and forsythiaside in the health product or medicament is not less than 1%.
9. The use of claim 1, wherein the ratio of the weight of the forsythin, forsythin derivatives or composition of forsythin and forsythiaside to the total weight of the health product or medicament is from 0.01 to 50: 100.
10. the use of claim 1, wherein the nutraceutical or pharmaceutical further comprises one or more of a radix Sophorae Tonkinensis extract, a fructus Xanthii extract, a herba Scutellariae Barbatae extract, a radix Sophorae Flavescentis extract, a herba Taraxaci extract, a flos Lonicerae extract, a rhizoma Zingiberis recens extract, a grape seed extract, a pomegranate seed extract, vitamin C and its derivatives, or vitamin E and its derivatives.
CN202010923837.9A 2020-09-04 2020-09-04 Application of phillyrin, phillyrin derivatives and composition of phillyrin and forsythiaside in resisting cytomegalovirus Pending CN114129584A (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CN202010923837.9A CN114129584A (en) 2020-09-04 2020-09-04 Application of phillyrin, phillyrin derivatives and composition of phillyrin and forsythiaside in resisting cytomegalovirus
CN202180050269.9A CN115955975A (en) 2020-09-04 2021-08-31 Forsythia suspensa component and optional ginseng component and uses thereof
KR1020237011165A KR20230061471A (en) 2020-09-04 2021-08-31 Forsythia fructus ingredients and optional Panax ginseng ingredients and uses thereof
JP2023514428A JP2023539681A (en) 2020-09-04 2021-08-31 Forsythia ingredients and optional ginseng ingredients and applications thereof
PCT/CN2021/115584 WO2022048529A1 (en) 2020-09-04 2021-08-31 Forsythiae fructus component and optional ginseng component, and use thereof
EP21863593.6A EP4209225A1 (en) 2020-09-04 2021-08-31 Forsythiae fructus component and optional ginseng component, and use thereof
BR112023003935A BR112023003935A2 (en) 2020-09-04 2021-08-31 COMPOSITIONS WITH FORSYTHIA SUSPENSA EXTRACT, FORSITIN AND FORSITIN DERIVATIVES, PHYLIGENIN AND OPTIONAL COMPONENT PANAX GINSENG AND APPLICATIONS
US18/024,173 US20230338454A1 (en) 2020-09-04 2021-08-31 Forsythia suspensa component and optional panax ginseng component and the application
CA3190270A CA3190270A1 (en) 2020-09-04 2021-08-31 Forsythia suspensa component and optional panax ginseng component and the application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010923837.9A CN114129584A (en) 2020-09-04 2020-09-04 Application of phillyrin, phillyrin derivatives and composition of phillyrin and forsythiaside in resisting cytomegalovirus

Publications (1)

Publication Number Publication Date
CN114129584A true CN114129584A (en) 2022-03-04

Family

ID=80438402

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010923837.9A Pending CN114129584A (en) 2020-09-04 2020-09-04 Application of phillyrin, phillyrin derivatives and composition of phillyrin and forsythiaside in resisting cytomegalovirus

Country Status (1)

Country Link
CN (1) CN114129584A (en)

Similar Documents

Publication Publication Date Title
CN108578421B (en) Application of phillyrin/phillygenin composition in preparation of medicines for relieving or/and treating viral diseases
CA2985862C (en) Application of ginseng extracts, ginsenoside and ginsenoside derivatives in preparation of medicines or health products for treating cytomegalovirus infection disorders
CN101658551A (en) Honeysuckle composition for resisting virus diseases of pigs
CN116096393A (en) Composition of ginsenoside Rg3 and Rg5 and antitumor medicines thereof
CN102008628A (en) Medicament for treating female genital tract virus infection and preparation method of sustained-release preparation of medicament
CN103800661A (en) Composition for improving immunity and relieving physical fatigue and preparation thereof
CN109106792B (en) Traditional Chinese medicine compound preparation for inhibiting blue ear virus and preparation method thereof
CN105796861B (en) Application of phillyrin derivative and phillyrin-phillygenin composition in preparation of medicine for improving immune function
CN103860616A (en) Manyprickle Acathopanax Root extrat, and preparation method and application thereof
CN115955975A (en) Forsythia suspensa component and optional ginseng component and uses thereof
KR20160115381A (en) Composition for antivirus comprising Ulmi Cortex extract as effective component
CN114129584A (en) Application of phillyrin, phillyrin derivatives and composition of phillyrin and forsythiaside in resisting cytomegalovirus
CN104274511A (en) Traditional Chinese medicinal composition for veterinary use and application thereof
CN108066350B (en) Application of phillyrin, phillyrin derivatives, and phillyrin-phillygenin composition in preparation of medicines for preventing and treating senile dementia
TW520287B (en) Hemopoietic function recovery agent and processed food using peanut seed peel treatment
CN101732644A (en) External preparation for treating gynaecopathia and dermatosis and preparation method thereof
CN101371861A (en) High-efficient antiviral medicament composition in chickweed as well as preparation method and use thereof
JPH0930983A (en) Apoptosis inhibitor
KR101715646B1 (en) INNATE IMMUNE ENHANCING AND ANTIVIRAL COMPOSITION COMPRISING EXTRACT OF Meliae Cortex
CN112294868B (en) Medicine for inactivating virus, sterilizing and activating immunity of organism
CN101607009B (en) Pharmaceutical composition for treating cold
CN114177220A (en) Composition of human and forsythia fruit and its antiviral medicine
CN113101331A (en) Thyme herb tea and preparation method and application thereof
CN110772557A (en) Application of kang' ai injection in preparing medicine for treating or preventing AIDS
CN111494499A (en) Astragalus membranaceus and acanthopanax senticosus soluble powder for poultry

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination